Miriplatin (INN; trade name Miripla) is a drug used to treat hepatocellular carcinoma (HCC).

It is a lipophilic platinum complex that is used in transcatheter arterial chemoembolization (TACE).

[1][2] Miriplatin was approved by Japan's Pharmaceuticals and Medical Devices Agency in 2009.

[1] This antineoplastic or immunomodulatory drug article is a stub.

You can help Wikipedia by expanding it.